Bladder Cancer Coverage from Every Angle

Roger Li, MD, on Combining Adenovirus CG007 With Pembrolizumab in Bladder Cancer

Posted: Friday, December 2, 2022

Roger Li, MD, of the H. Lee Moffitt Cancer Center, discusses the practical considerations of his findings on combining the adenovirus CG0070 with pembrolizumab in patients with non–muscle-invasive bladder cancer: the current standard of care, the underlying mechanism of the virus, adverse events, and next steps in the evolution of treatment.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.